Milestone Scientific (MLSS) Peer Comparison

$0.50

$0.12 (30.68%)

As on 28-Aug-2026 13:12EDT

Market cap

$42 Mln

Revenue (TTM)

$9 Mln

P/E Ratio

--

P/B Ratio

12

Div. Yield

0 %

Edit

	Milestone Scientific (MLSS)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Market cap ($ Mln)	42	12,753	10,906	10,222	9,762
Revenue ($ Mln)	9	1,505	613	785	2,589
Net Profit ($ Mln)	-4.14	160.59	-188.05	41.54	222.40
Net Margin (%)	-43.98	10.67	-30.68	5.29	8.59
RoE (%)	-131.89	10.86	-28.10	1.97	3.04
Price to Earnings	--	79.35	--	251.57	44.47
Price-To-Book	12.02	8.41	16.38	4.84	1.26

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Milestone Scientific (MLSS)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Operating Revenue	9.42	1,504.87	612.84	785.10	2,589.30
Cost of Revenue	2.86	483.98	127.96	384.30	1,245.50
Gross Profit	6.33	942.44	393.22	347.62	1,343.60
Operating Expenses	10.66	833.56	565.37	335.50	1,108.90
Operating Profit (EBIT)	-4.10	187.34	-80.49	65.30	235.00
Other Income	0.00	0.00	0.00	0.00	0.00
Profit before Tax	-4.14	203.83	-192.83	52.15	350.40
Provision for Tax	0.00	43.24	-4.79	10.61	128.00
Profit after Tax (Net Income)	-4.14	160.59	-188.05	41.54	222.40
Minority Interest	0.00	0.00	0.00	0.00	0.00
Consolidated Profit	0.00	93.19	0.00	0.00	0.00

Liabilities ($ Mln)

	Milestone Scientific (MLSS)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Shareholder's Funds	3.47	1,530.77	682.49	2,112.03	7,173.90
Minority Interest	0.00	0.00	0.00	0.00	0.00
Non-Current Liabilities	0.48	210.18	135.71	705.49	2,116.80
Current Liabilities	4.40	233.78	102.33	132.66	961.30
Total Liabilities	7.81	1,826.52	893.49	2,949.70	10,576.50

Assets ($ Mln)

	Milestone Scientific (MLSS)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Non-Current Assets	0.23	630.60	404.74	1,749.63	7,231.50
Current Assets	8.12	1,344.12	515.78	1,200.55	3,020.50
Total Assets	7.81	1,826.52	893.49	2,949.70	10,576.50
Total Debt*	0.62	212.71	102.84	690.94	1,203.70
Net Current Assets	0.00	1,110.35	413.45	1,067.90	2,059.20

Cashflow ($ Mln)

	Milestone Scientific (MLSS)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Cash From Operating Activities	-2.92	238.66	-46.34	117.42	532.20
Cash Flow from Investing Activities	-0.02	-404.59	-77.61	-298.47	-189.70
Cash from Financing Activities	0.79	26.53	11.89	-15.21	-283.20
Net Cash Inflow / Outflow	--	--	--	--	--

Ratios

Profitability Ratios

	Milestone Scientific (MLSS)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
ROCE (%)	-114.28	11.76	-22.53	1.79	8.98
ROE (%)	-131.89	10.86	-28.10	1.97	3.04
ROA (%)	-29.30	7.95	-18.00	1.36	2.02
EBIT Margin (%)	-43.56	13.63	-30.58	9.87	-5.99
Net Margin (%)	-43.98	10.67	-30.68	5.29	8.59
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

Growth Ratios

	Milestone Scientific (MLSS)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Revenue Growth (%)	3.72	17.55	41.55	16.49	1.37
EBIT Growth (%)	16.91	17.49	-116.42	920.91	-131.06
Net Profit Growth (%)	40.59	8.72	-102.66	400.42	-30.32
EPS Growth (%)	43.65	8.12	-96.88	394.30	-29.66
Book Value Growth (%)	-8.45	17.33	-12.65	2.16	2.19

Valuation Ratios

	Milestone Scientific (MLSS)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Price / Earnings	-3.92	68.93	-34.59	189.42	--
Price / Book Value	7.97	8.58	9.90	4.40	--
Dividend Yield (%)	--	--	--	--	--
EV/EBITDA	-4.05	53.25	-43.50	55.90	--
Market Cap ($ Cr)	--	--	--	--	--

Solvency Ratios

	Milestone Scientific (MLSS)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Debt to Equity	0.00	0.00	0.00	0.26	0.11
Short term debt to equity ratio	0.04	0.01	0.00	0.01	0.06
Current Ratio	1.85	5.75	5.04	9.05	3.14
Quick Ratio	1.14	3.86	4.46	7.64	2.33
Interest Coverage	-97.29	157.91	-38.31	3.36	8.18

Operating Efficiency Ratios

	Milestone Scientific (MLSS)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Debtors to sales (%)	11.18	12.65	22.67	20.09	17.06
Asset Turnover	0.67	0.74	0.59	0.26	0.24
Receivable days	24.05	46.54	60.95	72.41	65.39
Inventory Days	517.58	331.92	193.84	146.53	221.09
Payable days	169.30	26.16	60.19	29.05	37.02
Cash Conversion Cycle	372.32	352.30	194.60	189.88	249.46

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly